Key statistics
On Friday, PTC Therapeutics Inc (BH3:MUN) closed at 39.80, 0.00% below its 52-week high of 39.80, set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.80 |
---|---|
High | 39.80 |
Low | 39.80 |
Bid | 41.20 |
Offer | 41.60 |
Previous close | 39.80 |
Average volume | 13.80 |
---|---|
Shares outstanding | 76.92m |
Free float | 74.92m |
P/E (TTM) | -- |
Market cap | 3.41bn USD |
EPS (TTM) | -5.94 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:04 GMT.
More ▼
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
- CHMP Maintains Negative Opinion on Translarna™ Reexamination
- PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
- FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
More ▼